Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
NVIDIA (NVDA) 'Remains Our Hands-Down TOP PICK' - Citizens
-
Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy
-
Form 13F-NT CANTOR FITZGERALD & CO. For: Sep 30
-
Form 13F-NT Cantor Fitzgerald Europe For: Sep 30
-
Form 13F-HR CANTOR FITZGERALD, L. For: Sep 30
-
Euro Sun Welcomes Romania’s Steps to Adopt the European Union’s Critical Raw Materials Act and Reports Stronger Project Economics With NPV Rising to US$1.78 Billion at Rovina Valley
-
Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth
-
Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)
-
Applied Materials (AMAT) Shares At an Important Inflection - Cantor Fitzgerald
-
Stratasys (SSYS) PT Raised to $13.50 at Cantor Fitzgerald Amid Challenging Macro
-
Upexi (UPXI) PT Lowered to $6 at Cantor Fitzgerald Ex-Treasury Operations Value
-
Trevi (TRVI) First to Show Positive IPF Chronic Cough, RCC Data - Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Aardvark Therapeutics Inc (AARD)
-
Intuitive Machines (LUNR) Has Several Key Material Catalysts - Cantor Fitzgerald
-
Eupraxia's (EPRX) Blockbuster Opportunity Not Fully Priced In - Cantor Fitzgerald
-
Cantor Fitzgerald Starts DiaMedica Therapeutics Inc. (DMAC) at Overweight
-
Form 10-Q Cantor Fitzgerald Income For: Sep 30
-
Verastem Oncology prices $90 million stock offering at $7.25 per share
-
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
-
Verastem Oncology announces public offering of common stock
-
Verastem Oncology Announces Proposed Public Offering of Common Stock
-
Biohaven closes $200M public offering at $7.50 per share
-
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
-
Terawulf Inc. (WULF) PT Lowered to $18 at Cantor Fitzgerald
-
Grayscale Investments® Announces Public Filing of Registration Statement for Proposed Initial Public Offering
-
Securitize submits draft Form S-4 for CEPT merger to SEC
-
Securitize and Cantor Equity Partners II Announce Confidential Submission of Draft Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission
-
Serve Robotics' (SERV) 2000 Robots by Dec Plan Encouraging - Cantor Fitzgerald
-
Gossamer Bio's (GOSS) Seralitinib Data Likely Comes Out by Feb - Cantor Fitzgerald
-
SoundThinking (SSTI) PT Lowered to $16 at Cantor Fitzgerald on FY26 Expectations
-
Kodiak AI's (KDK) >3M Cumulative Autonomous Miles Encouraging - Cantor Fitzgerald
-
Polestar Automotive's (PSNY) Reverse Stock Split Awaited- Cantor Fitzgerald
-
Ascendis Pharma (ASND) Looks at Decreased FY2025-26 Revenues - Cantor Fitzgerald
-
Cantor Fitzgerald Downgrades Korro Bio Inc. (KRRO) to Neutral
-
FutureCrest Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing November 17, 2025
-
Orchid Island Capital Announces November 2025 Monthly Dividend and October 31, 2025 RMBS Portfolio Characteristics
-
AFM Capital Partners Announces Acquisition of Owens Industries as Add-On to Pro Products Holdings
-
Cantor Fitzgerald Downgrades Astria Therapeutics (ATXS) to Neutral
-
Eledon Pharmaceuticals prices $50 million public offering at $1.65 per share
-
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
-
Replimune's (REPL) RP1s Likely to Get Accelerated Approval - Cantor Fitzgerald
-
salesforce.com (CRM) Risk/Reward Set Good Amid AI-Fueled Fear - Cantor Fitzgerald
-
Centerspace (CSR) Needs a $75 Stock Price for Mid-6 Cap Rate -Cantor Fitzgerald
-
Biohaven prices $175 million public offering at $7.50 per share
-
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
-
Esperion Therapeutics' (ESPR) Portfolio Not Fully Priced In - Cantor Fitzgerald
-
Oklo (OKLO) PT Raised to $122 at Cantor Fitzgerald: 'Will be a Big Winner'
-
Fermi's (FRMI) New Campus Can Become US' Largest AI Data Centre - Cantor Fitzgerald
-
AMD (AMD) Focusing on Investments, Balance Sheet, Credit Rating - Cantor Fitzgerald
-
Eledon Pharmaceuticals launches public stock offering

